---
title: "GeoVax Labs | 8-K: FY2025 Revenue: USD 2.489 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282901131.md"
datetime: "2026-04-15T21:22:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282901131.md)
  - [en](https://longbridge.com/en/news/282901131.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282901131.md)
---

# GeoVax Labs | 8-K: FY2025 Revenue: USD 2.489 M

Revenue: As of FY2025, the actual value is USD 2.489 M.

EPS: As of FY2025, the actual value is USD -22.4.

#### Financial Results for the Year Ended December 31, 2025, Compared to 2024

#### Revenue

Revenue from government contracts for GeoVax Labs, Inc. decreased to $2.5 million in 2025 from $4.0 million in 2024, primarily due to the termination of the BARDA/RRPV contract .

#### Net Loss

GeoVax Labs, Inc. reported a net loss of - $21.5 million, or - $22.40 per share, for 2025, an improvement from a net loss of - $25.0 million, or - $120.46 per share, in 2024 .

#### Operating Expenses

Research and development (R&D) expenses were $18.1 million in 2025, down from $23.7 million in 2024, mainly due to discontinued costs from the BARDA/RRPV contract termination and lower costs for GEO-CM04S1 clinical trials and manufacturing . General and administrative (G&A) expenses increased to $6.0 million in 2025 from $5.4 million in 2024, driven by higher personnel costs, investor relations consulting, other programmatic expenses, patent costs, and stock-based compensation . Loss from operations was - $21.6 million in 2025, compared to - $25.1 million in 2024 .

#### Cash Position

Cash and cash equivalents were $3.1 million as of December 31, 2025, a decrease from $5.5 million as of December 31, 2024 .

#### Operational Metrics and Program Updates

GeoVax Labs, Inc. plans to initiate a pivotal Phase 3 clinical trial for GEO-MVA (Mpox/Smallpox Vaccine) in the second half of 2026, supported by a streamlined development pathway from the European Medicines Agency (EMA) . The company completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA . For GEO-CM04S1 (COVID-19 Vaccine), data readouts from multiple Phase 2 clinical trials for immunocompromised populations are anticipated in 2026, with interim findings from the CLL study showing superior immune responses . GeoVax Labs, Inc. completed Phase 1⁄2 clinical evaluation for Gedeptin® (Oncology) in advanced head and neck cancer and entered an exclusive license agreement with Emory University for combination use, with a Phase 2 trial planned for 2027 .

#### Outlook / Guidance

GeoVax Labs, Inc. prioritizes executing key GEO-MVA clinical and regulatory milestones and strengthening strategic partnerships . The company anticipates initiating the planned Phase 3 immuno-bridging study for GEO-MVA in the second half of 2026 . Additionally, data readouts for GEO-CM04S1 are expected in 2026, and a Phase 2 trial for Gedeptin® is planned for 2027 .

### Related Stocks

- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)

## Related News & Research

- [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md)
- [GeoVax Labs Signs Multiple Material Agreements](https://longbridge.com/en/news/270536080.md)
- [GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA](https://longbridge.com/en/news/270173602.md)
- [GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M](https://longbridge.com/en/news/282893057.md)
- [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://longbridge.com/en/news/286769314.md)